Clinical Trial Update: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke [Phase 1, Phase 2]

View source ↗

Summary

The trial evaluating autologous adipose-derived stromal cells for stroke has been withdrawn (Phases 1 and 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Autologous adipose-derived stromal cells (adipose-derived stromal cells)

Snippet

Sponsor: Ageless Regenerative Institute | Conditions: Stroke | Phase 1, Phase 2 | Status: WITHDRAWN